# Vikram Thermo (NSE: VIKRAMTH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VIKRAMTH · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹728 Cr, it ranks 1608th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 6.7% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹38 Cr (+39.3% year on year) and net profit ₹9 Cr (+109.3%), on a standalone basis. Promoters held 66.01% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹728 Cr |
| ROE | 6.7% (FY25) |
| ROCE | 35.8% (FY25) |
| Debt to equity | 0.05 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹38 Cr | +39.3% | ₹9 Cr | +109.3% | ₹2.72 |
| Q3 FY26 | ₹34 Cr | −0.9% | ₹11 Cr | +8.8% | ₹3.50 |
| Q2 FY26 | ₹35 Cr | +2.9% | ₹11 Cr | +13.2% | ₹3.53 |
| Q1 FY26 | ₹29 Cr | −8.2% | ₹8 Cr | — | ₹2.53 |
| Q4 FY25 | ₹27 Cr | −13.9% | ₹4 Cr | −17.4% | ₹1.30 |
| Q3 FY25 | ₹34 Cr | +8.8% | ₹10 Cr | +56.4% | ₹3.21 |
| Q2 FY25 | ₹34 Cr | −0.5% | ₹10 Cr | +18.7% | ₹3.14 |
| Q1 FY25 | ₹31 Cr | +5.4% | −₹16 Cr | −374.8% | −₹5.05 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹126 Cr | ₹8 Cr |
| FY24 | ₹126 Cr | ₹25 Cr |
| FY23 | ₹112 Cr | ₹17 Cr |
| FY22 | ₹93 Cr | ₹9 Cr |
| FY21 | ₹74 Cr | ₹12 Cr |
| FY20 | ₹56 Cr | ₹7 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 66.01%
- Domestic institutions: 0.26%
- Non-institutions: 33.74%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Anuh Pharma](https://app.pivotnow.in/stock/ANUHPHR) | ₹80.29 | ₹805 Cr | 19.6 | — |
| [Kilitch Drugs (India)](https://app.pivotnow.in/stock/KILITCH) | ₹215.00 | ₹752 Cr | 24.2 | — |
| [Zim Laboratories](https://app.pivotnow.in/stock/ZIMLAB) | ₹133.50 | ₹715 Cr | 112.2 | — |
| [Valiant Laboratories](https://app.pivotnow.in/stock/VALIANTLAB) | ₹131.05 | ₹712 Cr | — | — |
| [Amanta Healthcare](https://app.pivotnow.in/stock/AMANTA) | ₹182.55 | ₹709 Cr | 42.2 | — |
| [Gaudium IVF and Women Health](https://app.pivotnow.in/stock/GAUDIUMIVF) | ₹95.11 | ₹692 Cr | 24.3 | — |

## Questions and answers

### What is the market cap of Vikram Thermo?

Vikram Thermo's market capitalisation is ₹728 Cr (₹728 Cr) at the 22 Oct 2026 close, ranking 1608th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Vikram Thermo?

Return on equity was 6.7% in FY25 and return on capital employed was 35.8% in FY25 (standalone figures).

### Is Vikram Thermo a debt-free company?

Vikram Thermo is close to debt-free: its debt-to-equity ratio was 0.05 in FY25.

### What were Vikram Thermo's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Vikram Thermo reported revenue of ₹38 Cr, +39.3% year on year, and net profit of ₹9 Cr, +109.3% year on year.

### What is the shareholding pattern of Vikram Thermo?

As of 30 Jun 2026: promoters 66.01%, domestic institutions 0.26%, non-institutions 33.74%.

### Who are Vikram Thermo's competitors?

The listed Pharma & Healthcare companies closest to Vikram Thermo by market cap are Anuh Pharma, Kilitch Drugs (India), Zim Laboratories, Valiant Laboratories, Amanta Healthcare and Gaudium IVF and Women Health.

### Is Vikram Thermo a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Vikram Thermo's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIKRAMTH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.